Autism Spectrum Disorders and Schizophrenia Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories

Autism spectrum disorders (ASD) and schizophrenia spectrum disorders (SSD) share clinical and genetic components that have long been recognized. The two disorders co-occur more frequently than would be predicted by their respective prevalence, suggesting that a complex, multifactor association is involved. However, DSM-5 maintains the distinction between ASD, with core social and communication impairments, and SSD, including schizophrenia (SCZ), with hallucinations, delusions, and thought disorder as essential features. ASD and SSD have common biological underpinnings that may emerge early in development and unfold over time. One of the hypotheses supporting the similarities in the social and cognitive disturbances of ASD and SSD relates to abnormalities in the ratio of excitatory to inhibitory cortical activity (E/I imbalance). E/I imbalance in neurodevelopmental disorders could be the consequence of abnormalities in genes coding for glutamatergic and GABAergic receptors or synaptic proteins followed by system derangements. SSD and ASD have been characterized as polygenic disorders in which to the onset and progression of disease is triggered by interactions among multiple genes. Mammalian target of rapamycin signaling is under intense investigation as a convergent altered pathway in the two spectrum disorders. Current understanding of shared and divergent patterns between ASD and SSD from molecular to clinical aspects is still incomplete and may be implemented by the research domain criteria approach.

[1]  Wenjun Gao,et al.  NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia , 2013, Front. Cell. Neurosci..

[2]  E. Banks,et al.  De novo mutations in schizophrenia implicate synaptic networks , 2014, Nature.

[3]  P. Ashwood,et al.  The role of immune dysfunction in the pathophysiology of autism , 2012, Brain, Behavior, and Immunity.

[4]  Ben Alderson-Day,et al.  Are Hallucinations Due to an Imbalance Between Excitatory and Inhibitory Influences on the Brain? , 2016, Schizophrenia bulletin.

[5]  D. Porteous,et al.  DISC1-binding proteins in neural development, signalling and schizophrenia , 2012, Neuropharmacology.

[6]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[7]  L. DeLisi,et al.  Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia , 2011, Translational Psychiatry.

[8]  D. Porteous,et al.  Role of DISC1 in neural development and schizophrenia , 2007, Current Opinion in Neurobiology.

[9]  R. Rupprecht,et al.  Send Orders of Reprints at Reprints@benthamscience.net Targeting Glia Cells: Novel Perspectives for the Treatment of Neuro- Psychiatric Diseases , 2022 .

[10]  M. Costa-Mattioli,et al.  mTOR complexes in neurodevelopmental and neuropsychiatric disorders , 2013, Nature Neuroscience.

[11]  David A Lewis,et al.  The chandelier neuron in schizophrenia , 2011, Developmental neurobiology.

[12]  D. Lewis,et al.  GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. , 2008, Schizophrenia bulletin.

[13]  Irene Knuesel,et al.  Maternal immune activation and abnormal brain development across CNS disorders , 2014, Nature Reviews Neurology.

[14]  D. Murphy,et al.  Targeting Glia with N-Acetylcysteine Modulates Brain Glutamate and Behaviors Relevant to Neurodevelopmental Disorders in C57BL/6J Mice , 2015, Front. Behav. Neurosci..

[15]  A. Kolevzon,et al.  Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring , 2014, Journal of Neurodevelopmental Disorders.

[16]  R. Gao,et al.  Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. , 2015, Current molecular medicine.

[17]  K. Marwick,et al.  Social cognition in schizophrenia: a review of face processing. , 2008, British medical bulletin.

[18]  M. Gerstein,et al.  FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders , 2015, Cell.

[19]  A. Sato.  mTOR, a Potential Target to Treat Autism Spectrum Disorder , 2016, CNS & neurological disorders drug targets.

[20]  Ioan Opris,et al.  Prefrontal cortical minicolumn: from executive control to disrupted cognitive processing. , 2014, Brain : a journal of neurology.

[21]  Stephan Eliez,et al.  Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. , 2014, The American journal of psychiatry.

[22]  Hansen Wang,et al.  Reversing autism by targeting downstream mTOR signaling , 2013, Front. Cell. Neurosci..

[23]  Jacqueline N. Crawley,et al.  Negative Allosteric Modulation of the mGluR5 Receptor Reduces Repetitive Behaviors and Rescues Social Deficits in Mouse Models of Autism , 2012, Science Translational Medicine.

[24]  G. Blatt,et al.  Decreased GABAB receptors in the cingulate cortex and fusiform gyrus in Autism , 2010, Journal of neurochemistry.

[25]  D. Collier,et al.  Altered Social Behaviours in Neurexin 1α Knockout Mice Resemble Core Symptoms in Neurodevelopmental Disorders , 2013, PloS one.

[26]  L. Petersen,et al.  A comprehensive assessment of parental age and psychiatric disorders. , 2014, JAMA psychiatry.

[27]  R. Hommer,et al.  Schizophrenia and autism-related disorders. , 2015, Schizophrenia bulletin.

[28]  T. Südhof,et al.  A Neuroligin-4 Missense Mutation Associated with Autism Impairs Neuroligin-4 Folding and Endoplasmic Reticulum Export , 2009, The Journal of Neuroscience.

[29]  B. Bogerts,et al.  Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy , 2015, Schizophrenia Research.

[30]  Caroline E. Robertson,et al.  Reduced GABAergic Action in the Autistic Brain , 2016, Current Biology.

[31]  S. Horvath,et al.  Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology , 2011, Nature.

[32]  J. Rapoport,et al.  Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. , 2013, Child and adolescent psychiatric clinics of North America.

[33]  D. Balu.  The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. , 2016, Advances in pharmacology.

[34]  T. Südhof,et al.  An autism‐associated point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA receptor‐mediated synaptic transmission in hippocampus , 2011, The EMBO journal.

[35]  H. Simsek,et al.  Cytomorphological Effects of Mitomycin C on Urothelial Cells: Eosinophils May Be Clue to The Drug-Induced Changes , 2014, Cell journal.

[36]  N. de Lacy,et al.  Revisiting the relationship between autism and schizophrenia: toward an integrated neurobiology. , 2013, Annual review of clinical psychology.

[37]  J. Swann,et al.  Multiple Roles for Mammalian Target of Rapamycin Signaling in Both Glutamatergic and GABAergic Synaptic Transmission , 2012, The Journal of Neuroscience.

[38]  C. G. Pérez-García,et al.  ErbB4 in Laminated Brain Structures: A Neurodevelopmental Approach to Schizophrenia , 2015, Front. Cell. Neurosci..

[39]  Eric Hollander,et al.  Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics , 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[40]  M. Casanova,et al.  Review: Cortical construction in autism spectrum disorder: columns, connectivity and the subplate , 2016, Neuropathology and applied neurobiology.

[41]  Elodie Ey,et al.  Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments , 2014, PLoS genetics.

[42]  Anirvan Ghosh,et al.  Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders. , 2012, Trends in pharmacological sciences.

[43]  Qiang Zhou,et al.  NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease , 2013, Nature Reviews Neuroscience.

[44]  M. Garvey,et al.  The National Institute of Mental Health Research Domain Criteria and Clinical Research in Child and Adolescent Psychiatry. , 2016, Journal of the American Academy of Child and Adolescent Psychiatry.

[45]  Catherine Lord,et al.  Is schizophrenia on the autism spectrum? , 2011, Brain Research.

[46]  Laurent Mottron,et al.  Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia , 2011, Human Genetics.

[47]  M. E. Burns,et al.  cGMP in mouse rods: the spatiotemporal dynamics underlying single photon responses , 2015, Front. Mol. Neurosci..

[48]  B. Chattopadhyaya,et al.  GABAergic Circuit Dysfunctions in Neurodevelopmental Disorders , 2012, Front. Psychiatry.

[49]  A. Reichelt,et al.  The role of neurexins in schizophrenia and autistic spectrum disorder , 2012, Neuropharmacology.

[50]  D. Lewis,et al.  Dendritic spine pathology in schizophrenia , 2013, Neuroscience.

[51]  J. Frazier,et al.  "Autism-plus" spectrum disorders: intersection with psychosis and the schizophrenia spectrum. , 2013, Child and adolescent psychiatric clinics of North America.

[52]  S. Fatemi,et al.  The neurodevelopmental hypothesis of schizophrenia, revisited. , 2009, Schizophrenia bulletin.

[53]  Bruce N Cuthbert,et al.  The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology , 2014, World psychiatry : official journal of the World Psychiatric Association.

[54]  P. Thuras,et al.  GABAA Receptor Downregulation in Brains of Subjects with Autism , 2009, Journal of autism and developmental disorders.

[55]  Colin Kehrer,et al.  Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia , 2008, Frontiers in molecular neuroscience.

[56]  Deanna Greenstein,et al.  Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[57]  Daniel J. Faso,et al.  Context Effects on Facial Affect Recognition in Schizophrenia and Autism: Behavioral and Eye-Tracking Evidence. , 2016, Schizophrenia bulletin.

[58]  Neville E. Sanjana,et al.  Mice with Shank3 Mutations Associated with ASD and Schizophrenia Display Both Shared and Distinct Defects , 2016, Neuron.

[59]  J. Crawley,et al.  GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism , 2015, Neuropsychopharmacology.

[60]  J. Hutsler,et al.  Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders , 2010, Brain Research.

[61]  Anamika Banerjee,et al.  Neuregulin 1–erbB4 pathway in schizophrenia: From genes to an interactome , 2010, Brain Research Bulletin.

[62]  M. Buuse,et al.  Is the mTOR‐signalling cascade disrupted in Schizophrenia? , 2014, Journal of neurochemistry.